Pregnancy carries a high risk of thromboembolic complications, especially in the postpartum period. This risk is particularly high in women with inherited thrombophilias, among these antithrombin deficiency seems to carry the highest risk. In this case, the use of low molecular weight heparin (LMWH) is recommended, while the use of antithrombin concentrate is controversial. We report our experience of seven pregnancies occurred in five women: two, with a personal and familiar history negative for venous thromboembolism, were treated with LMWH during pregnancy and antithrombin concentrate immediately before and after the delivery. The other three women had a personal and familiar history positive for venous thromboembolism and were treated with LMWH and antithrombin concentrate during all the pregnancy and the postpartum period. No thromboembolic or hemorrhagic complications were observed in both groups, demonstrating that our strategy could be safe and effective.

Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: A single-center experience / Bruzzese, Antonella; Santoro, C.; Baldacci, E.; Ferretti, A.; Pieroni, Simone; Serrao, A.; Foa, R.; Chistolini, A.. - In: BLOOD COAGULATION & FIBRINOLYSIS. - ISSN 0957-5235. - 30:6(2019), pp. 304-307. [10.1097/MBC.0000000000000835]

Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: A single-center experience

BRUZZESE, ANTONELLA;Santoro C.;Baldacci E.;Ferretti A.;PIERONI, SIMONE;Serrao A.;Foa R.;Chistolini A.
2019

Abstract

Pregnancy carries a high risk of thromboembolic complications, especially in the postpartum period. This risk is particularly high in women with inherited thrombophilias, among these antithrombin deficiency seems to carry the highest risk. In this case, the use of low molecular weight heparin (LMWH) is recommended, while the use of antithrombin concentrate is controversial. We report our experience of seven pregnancies occurred in five women: two, with a personal and familiar history negative for venous thromboembolism, were treated with LMWH during pregnancy and antithrombin concentrate immediately before and after the delivery. The other three women had a personal and familiar history positive for venous thromboembolism and were treated with LMWH and antithrombin concentrate during all the pregnancy and the postpartum period. No thromboembolic or hemorrhagic complications were observed in both groups, demonstrating that our strategy could be safe and effective.
2019
antithrombin concentrate; congenital antithrombin deficiency; pregnancy
01 Pubblicazione su rivista::01a Articolo in rivista
Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: A single-center experience / Bruzzese, Antonella; Santoro, C.; Baldacci, E.; Ferretti, A.; Pieroni, Simone; Serrao, A.; Foa, R.; Chistolini, A.. - In: BLOOD COAGULATION & FIBRINOLYSIS. - ISSN 0957-5235. - 30:6(2019), pp. 304-307. [10.1097/MBC.0000000000000835]
File allegati a questo prodotto
File Dimensione Formato  
Bruzzese_Antithrombin_2019.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.69 MB
Formato Adobe PDF
2.69 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1313518
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact